There are currently 467 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University at Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
NCT05359848
Recruiting
Caloric restriction may alter the response to chemotherapy induced stress response and enhance its antitumor effect. This study intends to use an intermitted caloric restriction protocol with alternate days before the chemotherapy administration to enhance the cytotoxic effect generated by standard treatment of cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/06/2023
Locations: University at Buffalo / Great Lakes Cancer Care, Buffalo, New York +1 locations
Conditions: Medical Oncology, Integrative Oncology, Medical Nutrition Therapy
Register for Updates
A Sugar-Sweetened Beverage Reduction Intervention for Native American Men
NCT06029517
Recruiting
This clinical trial develops and tests a culturally-appropriate educational program (Indigenous SIPin) for reducing sugar-sweetened beverage consumption in men affiliated with Native American athletics communities. Sugary drinks are drinks like pop, soda, and juice. Increased sugar consumption may lead to an increased risk of chronic diseases, including obesity, diabetes, some types of obesity-related cancers, coronary heart disease, hypertension, and dental decay. A culturally sensitive program... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Cardiovascular Disorder, Coronary Artery Disease, Diabetes Mellitus, Obesity-Related Malignant Neoplasm
Register for Updates
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
NCT03595917
Recruiting
This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 25-40 people will take part in this research study. ABL001 Dasatinib (Sprycel®)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/04/2023
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
Register for Updates
Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
NCT04372524
Recruiting
This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant. By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aim... Read More
Gender:
All
Ages:
Between 0 years and 24 years
Trial Updated:
12/02/2023
Locations: Roswell Park Comprehensive Care Center, Buffalo, New York
Conditions: Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
Register for Updates
CapTemY90 for Grade 2 NET Liver Metastases
NCT04339036
Recruiting
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Register for Updates
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Recruiting
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Gender:
All
Ages:
4 months and above
Trial Updated:
11/21/2023
Locations: The Cystic Fibrosis Center of Western New York, Buffalo, New York
Conditions: Cystic Fibrosis
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
All
Ages:
21 years and below
Trial Updated:
11/20/2023
Locations: Womens and Childrens Hospital of Buffalo, Buffalo, New York
Conditions: Surgery, Anesthesia, Children
Register for Updates
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
NCT06144554
Recruiting
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
Gender:
All
Ages:
2 years and above
Trial Updated:
11/16/2023
Locations: Circuit Clinical, Buffalo, New York
Conditions: Type 1 Diabetes
Register for Updates
7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels
NCT05480761
Recruiting
This is a Phase 4, U.S. only, multi-center study using a 7-day therapeutic response dose (TRD) of commercial Sucraid® to assess the response of treatment in 1100 symptomatic pediatric (6 months to 17 years old) subjects with low, moderate, and normal sucrase activity determined by a disaccharidase assay via EGD within 1 year of the Screening Visit. This study will also explore the relationship between known genetic CSID mutations and sucrase activities via (EGD) disaccharidase assay (low, modera... Read More
Gender:
All
Ages:
Between 6 months and 17 years
Trial Updated:
11/14/2023
Locations: WNY Pediatric Gastroenterology, Buffalo, New York
Conditions: Congenital Sucrase-Isomaltase Deficiency, CSID, Sucrase Isomaltase Deficiency
Register for Updates
Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05177536
Recruiting
This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Multiple Myeloma
Register for Updates
Behavioral Parenting Skills As A Novel Target for Improving Pediatric Medication Adherence
NCT05587582
Recruiting
This study observes behavioral parenting skills to see whether it could be a novel target for improving pediatric medication adherence. This study may help researchers better understand the challenges parents face when giving their young child with an illness medicine at home and learn about various factors related to medication compliance in young children
Gender:
All
Ages:
18 years and above
Trial Updated:
11/09/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Lymphoblastic Leukemia
Register for Updates
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
NCT03384836
Recruiting
This phase Ib/II trial studies the side effects and best dose of propranolol hydrochloride when given together with pembrolizumab and how well they work in treating patients with stage IIIC-IV melanoma that cannot be removed by surgery. Pembrolizumab is a monoclonal antibody that "takes the brakes off the immune system" and thus allows for anti-tumor immune responses. Propranolol hydrochloride is a beta adrenergic blocking agent that can enhance immune cell responses when under stress. Giving pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/08/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates